Adoxa Pak and Bictegravir Sodium, Emtricitabine, and Tenofovir Alafenamide Fumarate

• Generic Name: doxycycline
• Dosage Forms: n.a.
• Other Brand Names: Acticlate, Adox Pak 2/100, Adoxa, Adoxa Pak 1/100, Adoxa Pak 1/150, Avidoxy, Monodox, Morgidox, Oraxyl, TargaDOX, Vibramycin, Adoxa CK, Adoxa Pak, Adoxa TT, Alodox, Avidoxy, Doryx, Mondoxyne NL, Oracea, Periostat Targadox, Vibramycin Calcium, Vibramycin Hyclate, Vibramycin monohydrate, Vibra-Tabs, Doxy 100, TargaDOX

Doxycycline is used to treat bacterial infections in many different parts of the body. It is also used to treat pimples and abscesses (usually on the face) that are caused by rosacea, also known as acne rosacea or adult acne.

Doxycycline delayed-release capsules, delayed-release tablets, and tablets and Acticlate® Cap capsules are also used to prevent malaria and treat anthrax infection after possible exposure and other conditions as determined by your doctor.

Doxycycline belongs to the class of medicines known as tetracycline antibiotics. It works by killing bacteria or preventing their growth. However, this medicine will not work for colds, flu, or other virus infections.

This medicine is available only with your doctor's prescription.

• Generic Name: bictegravir / emtricitabine / tenofovir alafenamide
• Dosage Forms: n.a.
• Other Brand Names: Biktarvy

Treatment of HIV-1 infection in antiretroviral-naive (have not previously received antiretroviral therapy) or antiretroviral-experienced (previously treated) adults.

Fixed combination of BIC/FTC/TAF used alone as a complete regimen for treatment of HIV-1 infection; concomitant use with other antiretrovirals not recommended.

For initial treatment in antiretroviral-naive adults, experts state BIC/FTC/TAF is a recommended INSTI-based regimen for most adults.

For antiretroviral-experienced adults, manufacturer states BIC/FTC/TAF can be used to replace the current antiretroviral regimen in those with plasma HIV-1 RNA levels <50 copies/mL on a stable antiretroviral regimen for ≥3 months who have no history of treatment failure and are infected with HIV-1 with no known substitutions associated with resistance to the antiretroviral components of the fixed combination (i.e., bictegravir, emtricitabine, tenofovir).